MRC is proud to offer the following Data Partner Service, entitling Data Partners to full access to all forthcoming analytical reports on targeted biotechnology/pharmaceutical companies, as well as updates on developments of all companies covered.
Prior examples of MRC's analyses that have been publicly divulged can be found in our executive summary on Amarin Corp (NASDAQ: AMRN): here, and summaries of analyses on Athenex (NASDAQ: ATNX), Acasti Pharma (NASDAQ: ACST), and recently, TG Therapeutics (NASDAQ: TGTX): here, here, and here, respectively.
Data Partners are further granted access to our proprietary investment portfolio, the "MRC Fund," including all positions, breakdown on position sizing, cost basis for each position, P/L, and ongoing updates on any changes made therein. A running tally of year-to-date P/L for the MRC Fund (+58.17% YTD as of 03/31/20), may be found here.
We also jointly offer consultation packages (located under drop-down menu to the right), whereby up to 1,000 words of email correspondence is provided per month on any/all of our past or present picks. Data Partners that have selected consultation packages are given priority in response-time from MRC, as well as time spent in response (depth of answer).
Signing up for multiple consultation packages by selecting "Additional Consultation Package(s)" from the drop-down menu, and then clicking "Add to Cart" one or more times with the same username/account, will increase the monthly word count of email consultation allotted to that account per month. For example, selecting "Data Partner Service w/ (1) Consultation Package," clicking "Add to Cart," and then selecting "Additional Consultation Package(s)," and clicking "Add to Cart" two (2) times, will grant that account three (3) consultation packages in total, or 3,000 words (~6-8 pages) of email correspondence per month.
Please note that all correspondence from MRC will be sent to the email address used to sign up.
The service may be canceled at any time, and will automatically renew unless canceled. Cancelations can be made upon request. Consultation packages are non-cumulative.
If you have any questions, please use our Contact Form to submit them.
Research reports, notifications of changes made in the MRC Fund portfolio of positions, or any other content disseminated by MRC are not recommendations to buy, sell, avoid, or sell short any security, and are for informational purposes only; we recommend securing the services of a registered investment
advisor (which we are not) and performing your own independent investigations
before acting on information from us.